CVS urges cost controls for new cholesterol drugs

February 18, 2015 12:24 PM

4 0

CVS urges cost controls for new cholesterol drugs

CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system "if rigid cost control mechanisms are not put in place."

Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer. CVS said they could eventually be used by as many as 15 million patients at an annual cost of up to $150 billion a year if priced at $7,000 to $12,000 a year, making it the highest-sellin...

Read more

To category page

Loading...